1. Frampton GM et al. Nat Biotechnol 2013; 31: 1023–1031.

2. Drilon A et al. Clin Cancer Res 2015; 21: 3631–3639.

3. Rankin A et al. Oncologist 2016; 21: 1306–1314.

4. Ross JS et al. Cancer 2016; 122: 2654–2662.

5. Suh JH et al. Oncologist 2016; 21: 684–691.

6. Hirshfield KM et al. Oncologist 2016; 21: 1315–1325.

7. FoundationOne®CDx Technical Specifications, 2018. Available at: www.rochefoundationmedicine.com/f1cdxtech (Accessed March 2019)

8. FoundationOne®Liquid Technical Specifications, 2018. Available at: https://www.foundationmedicine.com/genomic-testing/foundation-one-liquid (Accessed March 2019).

9. FoundationOne®Heme Technical Specifications, 2017. Available at: www.foundationmedicine.com/genomic-testing/foundation-one-heme (Accessed March 2019)

10. FoundationOne®CDx FDA Approval, 2017. Available at: https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170019a.pdf (Accessed March 2019).

11. FoundationOne®CDx Sample Report, 2018. Available at: www.rochefoundationmedicine.com/reporting (Accessed March 2019).

12. FoundationOne®CDx FDA Approval Press Release, 2017. Available at: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm587273.htm (Accessed March 2019).

13. Clark TA et al. J Mol Diagn 2018; 20: 686–702.

14. Roche Media Release, 2018. Available at: https://www.roche.com/media/releases/med-cor-2018-06-19.htm (Accessed March 2019).